Continuous subcutaneous insulin infusion for managing diabetes: women's health implications.
The use of continuous subcutaneous insulin infusion (CSII), also called insulin pump therapy, is increasing for management of type 1 diabetes. This article provides a comprehensive background on CSII, reviews recent studies comparing it to multiple daily insulin injections, offers strategies to troubleshoot potential problems, and discusses the implications of CSII for women's health across the lifespan.
Louisiana Tech University in Ruston, LA, USA. dhood@latech.edu
Donna G
DG
Hood
D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D015918:Infusion Pumps, Implantable; D007328:Insulin / Q000008:administration & dosage / Q000627:therapeutic use; D007332:Insulin Infusion Systems; D011247:Pregnancy; D011248:Pregnancy Complications / Q000517:prevention & control; D011788:Quality of Life; D016387:Women's Health
D007004:Hypoglycemic Agents; D007328:Insulin